Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | GPR3 | P46089 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9433849 | 0.98 | CYP2A6 (0.45) | CYP2A6CYP1A2L3MBTL1GPR3MAPT | |
| SCHEMBL2519509 | 0.78 | CYP2A6 (0.47) | CYP2A6CYP1A2L3MBTL1GPR3ALDH1A1 | |
| SCHEMBL9218101 | 0.77 | CYP2A6 (0.50) | CYP2A6CYP1A2GPR3ALDH1A1HSD17B10 | |
| SCHEMBL637928 | 0.77 | CYP2A6 (0.50) | CYP2A6CYP1A2L3MBTL1GPR3MAPT | |
| SCHEMBL29601221 | 0.77 | L3MBTL1 (0.46) | CYP2A6CYP1A2L3MBTL1MAPTLMNA | |
| SCHEMBL165745 | 0.77 | L3MBTL1 (0.46) | CYP2A6CYP1A2L3MBTL1MAPTLMNA | |
| Hydrochloric Acid SCHEMBL28363251 | 0.76 | MAPT (0.50) | CYP2A6CYP1A2L3MBTL1GPR3MAPT | |
| Ammonia Solution, Strong SCHEMBL13730044 | 0.76 | CYP2A6 (0.48) | CYP2A6CYP1A2L3MBTL1GPR3MAPT | |
| SCHEMBL4237853 | 0.75 | SMN1; SMN2 (0.43) | CYP1A2L3MBTL1MAPTLMNAALDH1A1 | |
| SCHEMBL31201809 | 0.75 | SMN1; SMN2 (0.43) | CYP1A2L3MBTL1MAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113651820-A | Urea compounds for dual IDO and TDO inhibitors | 正大天晴药业集团股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-110382500-B | Urea compounds for dual IDO and TDO inhibitors | 正大天晴药业集团股份有限公司 | 2021-08-10 | — | — | CN | disclosed |
| EP-3233827-B1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | ACRAF (IT) | 2020-07-08 | — | — | EP | disclosed |
| EP-3567035-A1 | N-SUBSTITUTED 2,5-DIOXO-AZOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Canbas Co. Ltd. (JP) | 2019-11-13 | — | — | EP | disclosed |
| EP-3088397-B1 | COMPOUNDS THAT ABROGATE THE CELL CYCLE G2 CHECKPOINT FOR USE IN THE TREATMENT OF CANCER | CANBAS CO LTD (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-10221144-B2 | Antibacterial compounds having broad spectrum of activity | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2019-03-05 | — | — | US | disclosed |
| US-20170369450-A1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-12-28 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| WO-2016096686-A1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2016-06-23 | — | — | WO | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-7186841-B2 | (2-imidazolyl)quinolin-4-yl aldehydes; immunomodulators, antiproliferative agents; metabolic disorders | AMGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186841-B2 | (2-imidazolyl)quinolin-4-yl aldehydes; immunomodulators, antiproliferative agents; metabolic disorders | AMGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186841-B2 | (2-imidazolyl)quinolin-4-yl aldehydes; immunomodulators, antiproliferative agents; metabolic disorders | AMGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1333834-A4 | ANTIINFLAMMATION AGENTS | AMGEN INC (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20050043330-A1 | Antiinflammation agents | AMGEN INC. (US) | 2005-02-24 | — | — | US | disclosed |
| US-6846834-B2 | Compounds contain fused carbocyclic or heterocyclic rings; modulate expression and/or function of proteins involved in inflammation, metabolism and cell proliferation | AMGEN INC. (US) | 2005-01-25 | — | — | US | disclosed |
| CN-1503673-A | Anti-inflammatory agent | �㽭�пؼ����ɷ�����˾ | 2004-06-09 | — | — | CN | disclosed |
| EP-1333834-A2 | ANTIINFLAMMATION AGENTS | Tularik Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002041843-A2 | ANTIINFLAMMATION AGENTS | TULARIK INC. (US) | 2002-05-30 | — | — | WO | disclosed |
| EP-0317416-A1 | Process for the preparation of 1-chloro-5-alkyl isoquinolines condensed with aromatic groups, the products so obtained and their use as medicines | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1989-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | CYP2A6 4408/4885CYP1A2 4552/4885L3MBTL1 2556/4885 |
| US-20050043330-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | CYP2A6 2362/4885CYP1A2 2068/4885L3MBTL1 4635/4885 |
| US-20170369450-A1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | MRPL21, ABCG2, CLPP | CYP2A6 2155/4885CYP1A2 2782/4885L3MBTL1 3582/4885 |
| US-10221144-B2 | Antibacterial compounds having broad spectrum of activity | MRPL21, ABCG2, CLPP | CYP2A6 2155/4885CYP1A2 2782/4885L3MBTL1 3582/4885 |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | CYP2A6 4408/4885CYP1A2 4552/4885L3MBTL1 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.